Skip to content
MedsAcross

Molecule

Diatrizoate

Also known as diatrizoate meglumine, diatrizoate sodium
Available on requestContrast media and diagnostics
Presentations
6
Brands
4
Manufacturers
2
Available from stock
0

Diatrizoate is a radiographic contrast agent indicated for retrograde cystourethrography. It is available as oral solution, injection and oral liquid for rectal and intravenous use. MedsAcross supplies Diatrizoate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

Pharmacological class
Radiographic Contrast Agent, X-Ray Contrast Activity
ATC classification
V08AA01 Diatrizoate · Iodinated contrast, subgroup V08AA
US FDA first approval
26 November 1954
EU status
Not recorded
Orphan designation
Not recorded
WHO essential medicine
Not recorded
India (CDSCO)
Not yet confirmed against CDSCO approval lists
Routes
Oral, Rectal, Intravenous, Intravesical
Dosage forms
Oral solution, Injection, Oral liquid
Identifiers
UNII 5UVC90J1LKRxCUI 3319CAS 117-96-4DrugBank DB00271Q411511

Clinical information

From the regulator-approved product information. Each section names its source.

Dosing overview

Preparation of the patient: Appropriate preparation is desirable for optimal results. A laxative the night before the examination and a low residue diet the day before the procedure are recommended. Dosage: The dose for retrograde use in cystography and voiding cystourethrography ranges from 25 to 300 mL depending on the age of the patient and the degree of bladder irritability, amounts greater than 300 mL may be used if the bladder capacity allows. Best results are obtained when the bladder is filled with the contrast agent. If desired, the preparation may be diluted with sterile water or sterile saline as indicated in the table below. Administration: After sterile catheterization, the bladder should be filled to capacity with Cystografin using a suitable sterile administration set. Care should be taken to avoid using excessive pressure.

Source: US FDA prescribing information

Contraindications

This preparation is contraindicated in patients with a hypersensitivity to salts of diatrizoic acid.

Source: US FDA prescribing information

Warnings and precautions

Severe sensitivity reactions are more likely to occur in patients with a personal or family history of bronchial asthma, significant allergies, or previous reactions to contrast agents. A history of sensitivity to iodine per se or to other contrast agents is not an absolute contraindication to the use of diatrizoate meglumine, but calls for extreme caution in administration.

Source: US FDA prescribing information

Side effects

Retrograde genitourinary procedures may cause such complications as hematuria, perforation of the urethra or bladder, introduction of infection into the genitourinary tract, and oliguria or anuria. If intravasation of this drug occurs, the reactions which may be associated with intravenous administration may possibly be encountered. Hypersensitivity or anaphylactoid reactions may occur. Severe reactions may be manifested by edema of the face and glottis, respiratory distress, convulsions or shock, such reactions may prove fatal unless promptly controlled by such emergency measures as maintenance of a clear airway and immediate use of oxygen and resuscitative drugs.

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

6 presentations of Diatrizoate, sorted by availability.

MedicineManufacturerRegisterAvailability
Diatrizoate 660 mg/100 mg per mL oral solutionOral, rectalGeneric name—US FDAAvailable on request
Gastrografin 660 mg/100 mg per mL oral liquidOral, rectalBracco DiagnosticsUS FDAAvailable on request
Cystografin 30000 mg/100 mL injectionIntravenousBracco DiagnosticsUS FDAAvailable on request
Cystografin 90000 mg/300 mL injectionIntravenousBracco DiagnosticsUS FDAAvailable on request
Cystografin Dilute 54000 mg/300 mL injectionIntravesicalBracco DiagnosticsUS FDAAvailable on request
MD Gastroview 600 mg/100 mg per mL oral solutionOral, rectalLiebel-FlarsheimUS FDAAvailable on request

Brands by market

4 brand names across 1 markets.

Brand names by country

Manufacturers

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

RegisterStatusSource
US FDAFirst approved 26 November 1954Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Questions and answers

Is Diatrizoate available for export from India?

Yes, on request. MedsAcross lists 6 presentations of Diatrizoate and sources them for licensed hospitals, importers and physicians against valid import documents.

What brand names does Diatrizoate have?

The catalogue lists 4 brand names for Diatrizoate, including Cystografin, Cystografin Dilute, Gastrografin, MD Gastroview.

Is Diatrizoate approved by the US FDA?

Yes. The US FDA first approved Diatrizoate on 26 November 1954, according to Drugs@FDA.

Does Diatrizoate need cold chain shipping?

No listed presentation of Diatrizoate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.

Which ATC class is Diatrizoate in?

Diatrizoate is classified under ATC code V08AA01 (Diatrizoate).

References

  1. Cystografin prescribing information (Bracco Diagnostics). U.S. National Library of Medicine, DailyMed. Retrieved 23 November 2025

Request Diatrizoate for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.